Sepsis Therapeutics Market

Sepsis Therapeutics Market (Drug Class: Aminoglycosides, Cephalosporin, Glycopeptide Antibiotics, Others; Route of Administration: Intravenous, Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Third-generation Drugs and Antimicrobial Therapy to Combat Septic Infections

The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.

Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an 'in vitro' bactericidal activity against vibrio vulnificus.

Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.

sepsis therapeutics market

Request a sample to get extensive insights into the Sepsis Therapeutics Market?

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients.

sepsis therapeutics market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Sepsis Therapeutics Market”?

Analysts’ View of Sepsis Therapeutics Market

The sepsis therapeutics market is predicted to exponentially grow from a value of ~US$ 3.2 billion that was accounted in 2018, to a value of ~US$ 6 billion by 2027. Healthcare providers are practicing early therapeutic plasma exchange in cases of septic shock in patients. This method is considered medically safe, and effective for septic shock patients. They are also introducing high doses of vasopressors for rapid hemodynamic improvement and favorable changes in the cytokine profile for patients observed with septic shock. However, in the case of GPIs, adverse effects related to safety and tolerability towards drugs is an ongoing challenge for healthcare companies. To overcome this challenge, manufacturers should introduce new antimicrobial agents in efficacious fourth- and fifth-generation drugs.

Sepsis Therapeutics Market: Overview

  • According to the latest report published by Transparency Market Research on the global sepsis therapeutics market for the historical year of 2017 and forecast period of 2019 to 2027, rise in investments in research & development and novel pipeline drugs are projected to boost the growth of the global sepsis therapeutics market during the forecast period.
  • The global sepsis therapeutics market generated ~US$ 3.2 Bn revenue in 2018, and is expected to expand at a CAGR of 7.5% from 2019 to 2027.

Novel Pipeline Drugs and Rise in Incidence Rate of Sepsis: A Key Driver

  • The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.
  • According to the United Nations University (UNU), the percentage of the world population above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.
  • Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.
  • Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.
  • Asahi Kasei Corporation is planning to launch ART-123 by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.
  • New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class Prominent

  • The cephalosporin segment dominated the global sepsis therapeutics market in 2018, and is expected to account for a major market share during the forecast period, as third-generation cephalosporins are commonly used to treat neonatal and infant sepsis. Cephalosporins also have the broadest gram-negative bacterial coverage. This is likely to drive the cephalosporin segment during the forecast period.
  • The others segment is projected to grow at significant CAGR during the forecast period. The use of combination therapy for the treatment of sepsis, such as cephalosporin plus an aminoglycoside, is a driving factor that is expected to propel the segment from 2019 to 2027.

Intravenous Administration Popular

  • The most common way to administer antibiotics is intravenously, as intravenous antibiotics reach tissues faster and at higher concentrations than oral antibiotics. The preference of the intravenous route for administration of drugs is expected to propel the segment during the forecast period.

North America to Dominate Global Sepsis Therapeutics Market

  • North America accounted for a major share of the global market in 2018, followed by Europe. The high prevalence and rise in incidence of sepsis in the U.S. and Canada, wide base of pharmaceutical companies in the U.S., and easy availability of drugs in the region were key factors responsible for the prominent share held by North America in the global sepsis therapeutics market in 2018.
  • According to a study published in the National Center for Biotechnology Information (NCBI), around 300 people per 100,000 individuals in the U.S. are affected by severe sepsis and septic shock
  • Europe was also an attractive market for sepsis therapeutics in 2018. High budget for research & development in the field of sepsis treatment and various initiatives taken by private and government institutions to promote awareness about sepsis are estimated to propel the market in Europe during the forecast period. Furthermore, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.
  • The market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with a rise in the demand for novel therapeutics among a significant patient population. The sepsis therapeutics market in Asia Pacific is driven by a large pool of patients with sepsis in China and Japan, and rise in investments by leading players in the region for the establishment of distribution channels.

Global Sepsis Therapeutics Market: Competitive Landscape

  • Detailed profiles of the manufacturers of sepsis therapeutics have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.
  • Key players operating in the global sepsis therapeutics market include -
    • INOTREM S.A.
    • Mylan N.V.
    • Asahi Kasei Corporation
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • RegeneRx
    • Adrenomed AG
    • AtoxBio
    • Endacea, Inc.

Global Sepsis Therapeutics Market: Key Developments

Major manufacturers in the global sepsis therapeutics market are adopting research collaboration, purchase and distribution agreement, and new product development strategies to strengthen their product portfolios and geographic presence in the international market. Key developments in the global sepsis therapeutics market are:

  • In August 2019, Pfizer, Inc. partnered with GlaxoSmithKline plc to form a joint venture to create the world’s largest over-the-counter (OTC) business.
  • In November 2018, Adrenomed AG received US$ 27 Mn funding from Wellington Partners and HBM Healthcare Investments to be utilized toward the clinical development of Adrecizumab.

In the global sepsis therapeutics market report, we have discussed individual strategies, followed by company profiles of the manufacturers of sepsis drugs. The ‘competitive landscape’ section is included in the global sepsis therapeutics market report to provide readers with a dashboard view of the key players operating in the global sepsis therapeutics market.

Segmentation of the Sepsis Therapeutics Market

TMR’s study on the sepsis therapeutics market includes information categorized into four sections - by drug class, by route of administration, by distribution channel, and by region. Changing industry trends and other crucial market dynamics that are associated with these four sections of the sepsis therapeutics market are discussed in detail.

Drug Class

Aminoglycosides

Cephalosporin

Glycopeptide Antibiotics

Others

Route of Administration

Intravenous

Oral

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of sepsis therapeutics market?

Sepsis therapeutics market to reach a value of ~US$ 6 billion by 2027

What is the anticipated CAGR of the sepsis therapeutics market in the forecast period?

Sepsis therapeutics market is expected to expand at a CAGR of 7.5% from 2019 to 2027

What are the key driving factors for the growth of the sepsis therapeutics market?

Sepsis therapeutics market is driven by increase in the number of products in the pipeline and rise in research & development expenditures

Which is the rising prominent segment in the sepsis therapeutics market?

The cephalosporin segment dominated the global sepsis therapeutics market, and is expected to account for a major market share during the forecast period

Who are the key players in the sepsis therapeutics market?

Key players in the global sepsis therapeutics market include INOTREM S.A., Mylan N.V., Asahi Kasei Corporation Pfizer, Inc., GlaxoSmithKline plc

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Sepsis Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug Class Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Sepsis Therapeutics Market Analysis and Forecasts, 2017–2027

    5. Market Outlook

        5.1. Regulatory Scenario 

        5.2. Pipeline Analysis

    6. Global Sepsis Therapeutics Market Analysis and Forecasts, by Drug Class 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug Class, 2017–2027

            6.3.1. Aminoglycosides

            6.3.2. Cephalosporin 

            6.3.3. Glycopeptide Antibiotics 

            6.3.4. Others 

        6.4. Market Attractiveness, by Drug Class 

    7. Global Sepsis Therapeutics Market Analysis and Forecasts, by Route of Administration 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Route of Administration, 2017–2027

            7.3.1. Intravenous 

            7.3.2. Oral

        7.4. Market Attractiveness, by Route of Administration 

    8. Global Sepsis Therapeutics Market Analysis and Forecasts, by Distribution Channel 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2027

            8.3.1. Hospital Pharmacies 

            8.3.2. Retail Pharmacies 

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness, by Distribution Channel 

    9. Global Sepsis Therapeutics Market Analysis and Forecasts, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific 

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Market Attractiveness, by Region

    10. North America Sepsis Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value  Forecast, by Drug Class, 2017–2027

            10.2.1. Aminoglycosides

            10.2.2. Cephalosporin 

            10.2.3. Glycopeptide Antibiotics 

            10.2.4. Others 

        10.3. Market Value Forecast, by Route of Administration, 2017–2027

            10.3.1. Intravenous 

            10.3.2. Oral

        10.4. Market Value  Forecast, by Distribution Channel, 2017–2027

            10.4.1. Hospital Pharmacies 

            10.4.2. Retail Pharmacies 

            10.4.3. Online Pharmacies

        10.5. Market Value  Forecast, by Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis 

            10.6.1. By Drug Class 

            10.6.2. By Route of Administration 

            10.6.3. By Distribution Channel 

            10.6.4. By Country

    11. Europe Sepsis Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017–2027

            11.2.1. Aminoglycosides

            11.2.2. Cephalosporin 

            11.2.3. Glycopeptide Antibiotics 

            11.2.4. Others 

        11.3. Market Value Forecast, by Route of Administration, 2017–2027

            11.3.1. Intravenous 

            11.3.2. Oral

        11.4. Market Value  Forecast, by Distribution Channel, 2017–2027

            11.4.1. Hospital Pharmacies 

            11.4.2. Retail Pharmacies 

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis 

            11.6.1. By Drug Class 

            11.6.2. By Route of Administration 

            11.6.3. By Distribution Channel 

            11.6.4. By Country/Sub-region

    12. Asia Pacific Sepsis Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017–2027

            12.2.1. Aminoglycosides

            12.2.2. Cephalosporin 

            12.2.3. Glycopeptide Antibiotics 

            12.2.4. Others 

        12.3. Market Value Forecast, by Route of Administration, 2017–2027

            12.3.1. Intravenous 

            12.3.2. Oral

        12.4. Market Value Forecast, by Distribution Channel, 2017–2027

            12.4.1. Hospital Pharmacies 

            12.4.2. Retail Pharmacies 

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis 

            12.6.1. By Drug Class 

            12.6.2. By Route of Administration 

            12.6.3. By Distribution Channel 

            12.6.4. By Country/Sub-region

    13. Latin America Sepsis Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017–2027

            13.2.1. Aminoglycosides

            13.2.2. Cephalosporin 

            13.2.3. Glycopeptide Antibiotics 

            13.2.4. Others 

        13.3. Market Value Forecast, by Route of Administration, 2017–2027

            13.3.1. Intravenous 

            13.3.2. Oral

        13.4. Market Value Forecast, by Distribution Channel, 2017–2027

            13.4.1. Hospital Pharmacies 

            13.4.2. Retail Pharmacies 

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis 

            13.6.1. By Drug Class 

            13.6.2. By Route of Administration 

            13.6.3. By Distribution Channel 

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Sepsis Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value  Forecast, by Drug Class, 2017–2027

            14.2.1. Aminoglycosides

            14.2.2. Cephalosporin 

            14.2.3. Glycopeptide Antibiotics 

            14.2.4. Others 

        14.3. Market Value Forecast, by Route of Administration, 2017–2027

            14.3.1. Intravenous 

            14.3.2. Oral

        14.4. Market Value  Forecast, by Distribution Channel, 2017–2027

            14.4.1. Hospital Pharmacies 

            14.4.2. Retail Pharmacies 

            14.4.3. Online Pharmacies

        14.5. Market Value  Forecast, by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis 

            14.6.1. By Drug Class 

            14.6.2. By Route of Administration 

            14.6.3. By Distribution Channel 

            14.6.4. By Country/Sub-region

    15. Competitive Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Company Profiles

            15.2.1. Mylan N.V. 

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Product Portfolio

                15.2.1.3. SWOT Analysis

                15.2.1.4. Strategic Overview

                15.2.1.5. Financial Overview

            15.2.2. Asahi Kasei Corporation 

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Product Portfolio

                15.2.2.3. SWOT Analysis

                15.2.2.4. Strategic Overview

                15.2.2.5. Financial Overview

            15.2.3. Pfizer, Inc. 

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Product Portfolio

                15.2.3.3. SWOT Analysis

                15.2.3.4. Strategic Overview

                15.2.3.5. Financial Overview

            15.2.4. GlaxoSmithKline plc 

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Product Portfolio

                15.2.4.3. SWOT Analysis

                15.2.4.4. Strategic Overview

                15.2.4.5. Financial Overview

            15.2.5. RegeneRx

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Product Portfolio

                15.2.5.3. SWOT Analysis

                15.2.5.4. Strategic Overview

                15.2.5.5. Financial Overview

            15.2.6. Adrenomed AG 

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Product Portfolio

                15.2.6.3. Strategic Overview

            15.2.7. AtoxBio

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8. ENDACEA, INC. 

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Product Portfolio

                15.2.8.3. Strategic Overview

            15.2.9. INOTREM S.A 

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Product Portfolio

                15.2.9.3. Strategic Overview

    List of Tables

    Table 01: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 02: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 03: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 04: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 05: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 06: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 07: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 08: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 09: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 10: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 11: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 12: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 13: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 14: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 15: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 16: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 17: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 18: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 19: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 20: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 21: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 22: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 23: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

    Table 24: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    List of Figures

    Figure 01: Global Sepsis Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Global Sepsis Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2018 

    Figure 04: Global Sepsis Therapeutics Market Revenue, by Drug Class (US$ Mn), 2018

    Figure 03: Global Sepsis Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2018 

    Figure 05: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

    Figure 07: Global Sepsis Therapeutics Market Value Share, by Route of Administration, 2018

    Figure 09: Global Sepsis Therapeutics Market Value Share, by Region, 2018

    Figure 06: Global Sepsis Therapeutics Market Value Share, by Drug Class, 2018

    Figure 08: Global Sepsis Therapeutics Market Value Share, by Distribution Channel, 2018

    Figure 10: Regulatory Approval Process - U.S.  

    Figure 11: Regulatory Approval Process - Canada

    Figure 12: Regulatory Approval Process - Europe 

    Figure 13: Regulatory Approval Process - Japan

    Figure 14: Regulatory Approval Process - India

    Figure 15: Global Sepsis Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 16: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminoglycosides, 2017–2027

    Figure 17: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Cephalosporin, 2017–2027

    Figure 18: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Glycopeptide Antibiotics, 2017–2027

    Figure 19: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017–2027

    Figure 20: Global Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 21: Global Sepsis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

    Figure 22: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Intravenous, 2017–2027

    Figure 23: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Oral, 2017–2027

    Figure 24: Global Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 25: Global Sepsis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

    Figure 26: Global Sepsis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

    Figure 27: Global Sepsis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

    Figure 28: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

    Figure 29: Global Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 30: Global Sepsis Therapeutics Market Value Share Analysis, by Region 2018 and 2027

    Figure 31: Global Sepsis Therapeutics Market Attractiveness, by Region, 2019–2027

    Figure 32: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 33: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Country, 2018 and 2027

    Figure 34: North America Sepsis Therapeutics Market Attractiveness Analysis, by Country, 2019?2027

    Figure 35: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

    Figure 36: North America Sepsis Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027

    Figure 37: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

    Figure 38: North America Sepsis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019–2027

    Figure 39: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

    Figure 40: North America Sepsis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 41: Europe Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 42: Europe Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 43: Europe Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019?2027

    Figure 44: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

    Figure 45: Europe Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 46: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

    Figure 47: Europe Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 48: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

    Figure 49: Europe Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 50: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 51: Asia Pacific Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 52: Asia Pacific Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 53: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

    Figure 54: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 55: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

    Figure 56: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 57: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

    Figure 58: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 59: Latin America Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 60: Latin America Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 61: Latin America Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 62: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

    Figure 63: Latin America Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 64: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

    Figure 65: Latin America Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 66: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

    Figure 67: Latin America Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 68: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 69: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 70: Middle East & Africa Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

    Figure 71: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

    Figure 72: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

    Figure 73: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

    Figure 74: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

    Figure 75: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

    Figure 76: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Copyright © Transparency Market Research, Inc. All Rights reserved